Granules India Q2 FY27 slides: record revenue amid margin pressure By Investing.com
NiveshIQ
NSE: GRANULES · Healthcare
Granules India Ltd.
₹820.70▼ ₹19.05 (-2.27%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on GRANULES. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Granules India Ltd.
Granules India Limited is a diversified pharmaceutical manufacturer that produces active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), finished dosage forms (FDs), and peptide contract development and manufacturing services (CDMO) for both domestic and international markets. The company’s revenue mix is driven by high-volume generic APIs such as paracetamol, metformin, and ibuprofen, alongside specialty peptide products and complex generics in therapeutic areas including anti‑diabetic, anti‑viral, and anti‑cancer. In Q2 FY27, Granules India reported a record revenue of ₹5,632 crore, up 20% YoY, while net profit rose 39% to ₹662 crore, reflecting improved EBITDA margins despite cost pressures. Competitive positioning is strengthened by a robust manufact
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹4,506 Cr -0.12% | ₹4,482 Cr -0.55% | ₹5,366 Cr +19.73% |
| EBITDA Margin | 18.99% | 21.09% | 22.09% |
| Net Profit | ₹425.81 Cr -17.57% | ₹501.52 Cr +17.78% | ₹595.02 Cr +18.64% |
| EPS | ₹16.73 | ₹20.69 | ₹24.47 |
Annual figures in Indian Rupees (Crores). Source: company filings (NSE).
Recent News
Granules India Q2 net profit rises 39%
Granules India’s Q2 net up 39% at ₹182 crore
🔒
+ 3 more stories about Granules India Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹1, 477 Cr, PAT ₹180 Cr, EPS ₹7.26, EBITDA margin 22.9%. Growth context: revenue YoY +22.0%, PAT YoY +63.0%, revenue QoQ +0.4%, PAT QoQ -10.7%. Street verdict: miss, revenue surprise -1.6%, PAT surprise -5.7%.
Management commentary points to product launches, approvals, and therapy-mix improvement and new capacity addition and c...
FY26 (last completed FY): revenue ₹5, 366 Cr, PAT ₹595 Cr, EBITDA margin 22.1%, EPS ₹24.47. Year-on-year: revenue YoY +1...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantMore Healthcare stocks
Everything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for GRANULES
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track GRANULES alongside your other holdings
Unlock full GRANULES research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Granules India Ltd.?
NiveshIQ detects active intelligence signals for Granules India Ltd. (GRANULES) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Granules India Ltd.?
Granules India Ltd. operates in the Healthcare sector with a market capitalisation of ₹2,165,373.3L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.